Fiche société
Axsome Therapeutics, Inc.
Traitements, essais et publications liés.
Traitements5programmes
Essais3liés
Publications0liées
SourceDBlocale
Traitements
5| Molécule | Indication / population | Phase | Objectif | Pays | Résultat |
|---|---|---|---|---|---|
| AXS-05This trial was a multi-center, double-blind, placebo-controlled, randomized study to evaluate the efficacy and safety of AXS-05 compared to placebo for the treatment of agitation associated with Alzheimer's disease. | Alzheimer | Phase 3 | À vérifier | United States, Puerto Rico | À vérifier |
| AXS-14 (esreboxetine)This is a Phase 3, multi-center, 52-week, open-label trial to evaluate the long-term safety and efficacy of AXS-14 in the management of fibromyalgia. | Myopathies | Phase 3 | À vérifier | United States | À vérifier |
| AXS-05This trial was a multi-center, double-blind, placebo-controlled, randomized study to evaluate the efficacy and safety of AXS-05 compared to placebo for the treatment of agitation associated with Alzheimer's disease. | Alzheimer | Phase 3 | À vérifier | United States, Puerto Rico | À vérifier |
| AXS-14 (esreboxetine)This is a Phase 3, multi-center, 52-week, open-label trial to evaluate the long-term safety and efficacy of AXS-14 in the management of fibromyalgia. | Myopathies | Phase 3 | À vérifier | United States | À vérifier |
| AXS-14 (esreboxetine)This is a Phase 3, multi-center, 52-week, open-label trial to evaluate the long-term safety and efficacy of AXS-14 in the management of fibromyalgia. | Myopathies | Phase 3 | À vérifier | United States | À vérifier |
Essais cliniques
3| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| AXS-14 (esreboxetine) | Myopathies | Phase 3 | NCT07398417 | FORWARD — Fibromyalgia Response With Esreboxetine Evaluated Using a Randomized Withdrawal Research Design | RECRUITING |
| AXS-14 (esreboxetine) | Myopathies | Phase 3 | NCT07637162 | Open-Label Safety Study of AXS-14 in Subjects With Fibromyalgia | ENROLLING_BY_INVITATION |
| AXS-05 | Alzheimer | Phase 3 | NCT05557409 | ADVANCE-2 — A Study to Assess the Efficacy and Safety of AXS-05 in Subjects With Alzheimer's Disease Agitation | COMPLETED |
Publications
0| Molécule | Indication / population | Titre | Journal | Date |
|---|---|---|---|---|
| Aucune publication. | ||||